title: Treatment of malignant pleural mesothelioma with liposomized doxorubicine: prolonged time to progression and good survival. A Nordic study.
authors.affiliation: Department of Lung Medicine and Allergology, Karolinska University Hospital, Solna, Stockholm, Sweden. gunnar.hillerdal@karolinska.se
authors.forename: Gunnar
authors.initials: G
authors.lastname: Hillerdal
authors.forename: Jens Benn
authors.initials: JB
authors.lastname: Sorensen
authors.forename: Stein
authors.initials: S
authors.lastname: Sundström
authors.forename: Anders
authors.initials: A
authors.lastname: Vikström
authors.forename: Anders
authors.initials: A
authors.lastname: Hjerpe
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage* / Q000009:adverse effects; D001769:Blood / Q000187:drug effects; D018450:Disease Progression; D004317:Doxorubicin / Q000008:administration & dosage* / Q000009:adverse effects; D004334:Drug Administration Schedule; D004890:Erythema / Q000139:chemically induced; D005260:Female; D006801:Humans; D008081:Liposomes; D008297:Male; D008654:Mesothelioma / Q000188:drug therapy* / Q000401:mortality / Q000503:physiopathology; D008875:Middle Aged; D010997:Pleural Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000503:physiopathology; D011788:Quality of Life; D015996:Survival Rate; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D000903:Antibiotics, Antineoplastic; D008081:Liposomes; D004317:Doxorubicin